论文部分内容阅读
目的:探讨分析复合乳酸杆菌在治疗肝硬化失代偿期患者中的效果。方法:选择2011年1月~2014年12月间在我院住院治疗的54例肝硬化失代偿期患者为研究对象,随机分为观察组和对照组各27例,选取同时期健康体检者27例为健康对照组。观察组患者接受复合乳酸杆菌联合肝硬化常规治疗,对照组仅接受肝硬化常规治疗。治疗8周后,比较对照组和观察组治疗前后及健康对照组患者血浆ALT、AST、内毒素、IL-1β、TNF-α、血氨及消化道症状积分的差异。结果:观察组和对照组患者治疗前血浆ALT、AST、内毒素、IL-1β、TNF-α、血氨水平及消化道症状积分差异无统计学意义(P>0.05),均明显高于健康对照组(P<0.05);治疗后两组患者上述指标均明显降低(P<0.05),但观察组较对照组下降更为明显(P<0.05)。结论:复合乳酸杆菌联合常规疗法在肝硬化失代偿期患者的治疗方面发挥了重要作用,值得临床推广。
Objective: To investigate the effect of Lactobacillus complex in the treatment of patients with decompensated liver cirrhosis. Methods: 54 patients with decompensated cirrhosis who were hospitalized in our hospital from January 2011 to December 2014 were randomly divided into observation group (27 cases) and control group (27 cases) 27 cases were healthy control group. Patients in the observation group received routine treatment with Lactobacillus combined with cirrhosis, while patients in the control group received conventional treatment of liver cirrhosis only. After 8 weeks of treatment, the difference of ALT, AST, endotoxin, IL-1β, TNF-α, blood ammonia and gastrointestinal symptom scores in the control group and the observation group were compared before and after treatment and the healthy control group. Results: There was no significant difference in plasma ALT, AST, endotoxin, IL-1β, TNF-α, blood ammonia level and gastrointestinal symptom scores before and after treatment in observation group and control group (all P> 0.05) (P <0.05). After treatment, the above indexes in the two groups were significantly decreased (P <0.05), but the observation group was more obvious than the control group (P <0.05). Conclusion: Lactobacillus combined with conventional therapy plays an important role in the treatment of patients with decompensated cirrhosis and is worthy of clinical promotion.